The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

A study comparing oral glucose-lowering agents to insulin for gestational diabetes found no non-inferiority in preventing ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...